Join Growin Stock Community!

Benitec biopharma inc.BNTC.US Overview

US StockHealthcare
(No presentation for BNTC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BNTC AI Insights

BNTC Overall Performance

BNTC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BNTC Recent Performance

0.09%

Benitec biopharma inc.

0.05%

Avg of Sector

-0.31%

S&P500

BNTC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BNTC Key Information

BNTC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BNTC Profile

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Price of BNTC

BNTC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BNTC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.76
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2770.13
PB Ratio
2.00
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.76
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2770.13
PB Ratio
2.00
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is BNTC's latest earnings report released?

    The most recent financial report for Benitec biopharma inc. (BNTC) covers the period of 2026Q2 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BNTC's short-term business performance and financial health. For the latest updates on BNTC's earnings releases, visit this page regularly.

  • How much debt does BNTC have?

    As of the end of the reporting period, Benitec biopharma inc. (BNTC) had total debt of 987K, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BNTC have?

    At the end of the period, Benitec biopharma inc. (BNTC) held Total Cash and Cash Equivalents of 188.96M, accounting for 0.99 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What is the FCF of BNTC?

    Benitec biopharma inc. (BNTC)'s Free Cash Flow (FCF) for the period is -3.79M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 50.91% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of BNTC?

    The latest valuation data shows Benitec biopharma inc. (BNTC) has a Price-To-Earnings (PE) ratio of -8.41 and a Price/Earnings-To-Growth (PEG) ratio of -0.72. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.